Autovaccination Plus Heat-Inactivated Autologous Plasma in Aids Patients

Brüster, H; Kuntz, BarbaraM.E.; Scheja, J. W.

doi:10.1016/s0140-6736(88)92105-8

Cited by 7 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study at the University of Dusseldorf, which was conducted by Bruster et al, the 14 HIV-positive patients received autologous lymphocytes followed by boost with heat-inactivated autologous plasma; of these 12 have shown clear and often major clinical improvement [84]. What is remarkable with this study is that the observed clinical effect was attributed to the consequence of autovaccination rather than of immune reconstitution.…”

Section: Peripheral Blood-derived Live Vaccinesmentioning

confidence: 60%

See 1 more Smart Citation

Therapeutic AIDS Vaccines

Bourinbaiar¹,

Root‐Bernstein²,

Abulafia-Lapid³

et al. 2006

CPD

View full text Add to dashboard Cite

Therapeutic HIV vaccines represent promising strategy as an adjunct or alternative to current antiretroviral treatment options for HIV. Unlike prophylactic AIDS vaccines designed to prevent HIV infection, therapeutic vaccines are given to already infected individuals to help fight the disease by modulating their immune response. The first immunotherapeutic trial in AIDS patients was conducted in 1983. Since then several dozen conventional therapeutic vaccine trials have been carried out. Unfortunately, the results have consistently shown that while HIV-specific immune responses were evident as a result of vaccination, the clinical improvement has been seldom observed. The instances of the apparent clinical benefit were invariably associated with unconventional vaccines that acted in accord with the principles of alloimmunization and/or autologous vaccination. All such vaccines were derived from the blood of HIV carriers or a cell culture and thus they inherently contained allo- or self-antigens unrelated to HIV. This intriguing observation raises the issue whether this clinically successful approach has been unduly neglected. The current strategy biased toward vaccines, which have shown little evidence of clinical efficacy, needs to be diversified and supplemented with research on alternative vaccine approaches geared toward immune tolerance induction.

show abstract

Section: Peripheral Blood-derived Live Vaccinesmentioning

confidence: 60%

“…However, in few studies the authors were aware of the alloimmunizing aspect of lymphocyte transfusion and have ascribed it to the observed clinical effect [82,84,101]. From immunological viewpoint, this approach is not much different from the approach relying on immunization with inactivated lymphocytes.…”

Section: Peripheral Blood-derived Live Vaccinesmentioning

confidence: 99%